Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Wednesday morning. The brokerage issued a hold rating on the stock.

A number of other equities research analysts have also weighed in on EKSO. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, March 4th. Lake Street Capital reduced their target price on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th.

Ekso Bionics Stock Up 11.1 %

NASDAQ EKSO opened at $0.50 on Wednesday. The business’s 50-day moving average is $0.54 and its 200 day moving average is $0.77. The stock has a market capitalization of $12.41 million, a PE ratio of -0.77 and a beta of 1.43. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. Ekso Bionics has a 1 year low of $0.34 and a 1 year high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The business had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. Sell-side analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.